Abstract 308P
Background
We investigated the landscape of clinically relevant mutations in ctDNA from NSCLC patients in East Asia tested by a commercially available comprehensive next generation sequencing (NGS) assay (Guardant360) as part of clinical practice. This assay identifies single nucleotide variants (SNV), insertions (ins) and deletions (del), fusions, and amplifications (amp), with complete exon sequencing of multiple genes including EGFR, ERBB2, and KRAS.
Methods
Test results from Hong Kong, Korea, Taiwan, Japan and Southeast Asia were reviewed (cut-off June 2020). We identified cases with a diagnosis of “lung cancer,” excluding neuroendocrine, sarcomatoid, and pure squamous histology. Samples from patients enrolled in prospective clinical trials were excluded. Clinically relevant biomarkers were mutations in EGFR, ERBB2, or KRAS; BRAF V600E; MET amp or exon 14 skipping; and ALK, ROS1, RET, or NTRK1 fusions. Synonymous mutations and variants of unknown significance were not considered.
Results
Plasma from 1219 advanced non-squamous NSCLC patients was tested. Samples came from 663 women and 556 men, median age 62 years. Median turnaround time was 7 days from sample receipt to report. ctDNA was identified in 1034 samples (85% detection rate), with median variant allele fraction 0.6%. There were 718 samples (69%) with alterations in at least one clinically relevant biomarker: EGFR (49%), KRAS (8%), ERBB2 (4%), ALK (3%), RET (2%), MET (2%), BRAF (1%), and ROS1 (<1%). Co-mutations were detected in <1%. Potentially actionable EGFR alterations other than L858R or exon 19 del were found in 106 samples (13%), including exon 19 ins (1); exon 20 ins (25); and activating SNV (80) such as L718X (14), L861Q (7), G719A (7), and E709A (5). KRAS G12C was present in 22 samples (2%).
Conclusions
In the clinical practice setting, comprehensive NGS detected relevant biomarkers in 69% of plasma samples with ctDNA from patients with advanced non-squamous NSCLC. Using a single assay, both common and rare driver mutations could be found in a timely manner, obviating the need for multiple tests to identify less common actionable alterations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Guardant Health AMEA.
Funding
Has not received any funding.
Disclosure
B.C. Cho: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Novartis; Honoraria (self), Research grant/Funding (self): Bayer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Honoraria (self), Research grant/Funding (institution): MOGAM Institute; Honoraria (self), Research grant/Funding (institution): Dong-A ST; Honoraria (self), Research grant/Funding (institution), Licensing/Royalties: Champions Oncology; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Janssen; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Yuhan; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Ono; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): MSD; Advisory/Consultancy, Research grant/Funding (institution): Medpacto; Advisory/Consultancy, Research grant/Funding (institution): Eli Lilly; Advisory/Consultancy, Research grant/Funding (institution): Blueprint Medicines; Advisory/Consultancy: Boehringer-Ingelheim; Advisory/Consultancy: Roche; Advisory/Consultancy: BMS; Advisory/Consultancy: Pfizer; Honoraria (self): Guardant Health AMEA; Advisory/Consultancy: Takeda; Research grant/Funding (institution): AbbVie. H.H.F. Loong: Advisory/Consultancy, Travel/Accommodation/Expenses: Boehringer-Ingelheim; Advisory/Consultancy: Celgene; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eli-Lilly; Advisory/Consultancy: Illumina; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy: Merck Serono; Advisory/Consultancy: Takeda; Speaker Bureau/Expert testimony: AbbVie; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Bayer; Speaker Bureau/Expert testimony: Eisai; Speaker Bureau/Expert testimony: Guardant Health; Research grant/Funding (institution), Travel/Accommodation/Expenses: MSD; Travel/Accommodation/Expenses: Pfizer; Research grant/Funding (institution): Mundipharma. H.R. Kim: Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: Bristol-Myers Squibb; Honoraria (self): Ono Pharmaceutical; Honoraria (self): Roche. M. Lee: Full/Part-time employment: Guardant Health AMEA. S. Olsen: Full/Part-time employment: Guardant Health AMEA; Shareholder/Stockholder/Stock options: Guardant Health, Inc.; Shareholder/Stockholder/Stock options: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
372P - Treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): Real-world experience in Singapore from the KINDLE study
Presenter: Ross A. Soo
Session: e-Poster Display Session
373P - Chromatin accessibility reveals potential prognostic value of the peak set associated with smoking history in patients with lung adenocarcinoma
Presenter: Jianlian Deng
Session: e-Poster Display Session
384P - BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
Presenter: Stefanie Schalm
Session: e-Poster Display Session
385P - Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
Presenter: Fabrice Barlesi
Session: e-Poster Display Session
386P - A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: LI Zhou
Session: e-Poster Display Session
387P - Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C
Presenter: Tomonori Hirashima
Session: e-Poster Display Session
388P - Biosimilar TAB008 compared with bevacizumab in advanced non-squamous, non-small cell, EGFR wildtype lung cancer patients
Presenter: Zhen Zhou
Session: e-Poster Display Session
389P - Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%
Presenter: Yi-Long Wu
Session: e-Poster Display Session
391P - Economic impact of next-generation sequencing (NGS) versus single-gene testing modalities to detect genomic alterations (GAs) in metastatic non-small cell lung cancer (mNSCLC) in Asia
Presenter: Herbert Loong
Session: e-Poster Display Session
392P - Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALK-positive non-small cell lung cancer patients with brain metastases in China
Presenter: Zhixin Qiu
Session: e-Poster Display Session